We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Whole-tumor apparent diffusion coefficient measurements in nephroblastoma: Can it identify blastemal predominance?
- Authors
Littooij, Annemieke S.; Sebire, Neil J.; Olsen, Øystein E.
- Abstract
<bold>Purpose: </bold>To explore the potential relation between whole-tumor apparent diffusion coefficient (ADC) parameters in viable parts of tumor and histopathological findings in nephroblastoma.<bold>Materials and Methods: </bold>Children (n = 52) with histopathologically proven nephroblastoma underwent diffusion-weighted magnetic resonance imaging (MRI) (1.5T) before preoperative chemotherapy. Of these, 25 underwent an additional MRI after preoperative chemotherapy, shortly before resection. An experienced reader performed the whole-tumor ADC measurements of all lesions, excluding nonenhancing areas. An experienced pathologist reviewed the postoperative specimens according to standard SIOP guidelines. Potential associations between ADC parameters and proportions of histological subtypes were assessed with Pearson's or Spearman's rank correlation coefficient depending on whether the parameters tested were normally distributed. In case the Mann-Whitney U-test revealed significantly different ADC values in a subtype tumor, this ADC parameter was used to derive a receiver operating characteristic (ROC) curve.<bold>Results: </bold>The 25th percentile ADC at presentation was the best ADC metric correlated with proportion of blastema (Pearson's r = -0.303, P = 0.026). ADC after preoperative treatment showed moderate correlation with proportion stromal subtype at histopathology (r = 0.579, P = 0.002). By ROC analysis, the optimal threshold of median ADC for detecting stromal subtype was 1.362 × 10-3 mm2 /s with sensitivity and specificity of 100% (95% confidence interval [CI] 0.65-1.00) and 78.9% (95% CI 0.57-0.92), respectively.<bold>Conclusion: </bold>ADC markers in nephroblastoma are related to stromal subtype histopathology; however, identification of blastemal predominant tumors using whole-tumor ADC measurements is probably not feasible.<bold>Level Of Evidence: </bold>3 J. MAGN. RESON. IMAGING 2017;45:1316-1324.
- Publication
Journal of Magnetic Resonance Imaging, 2017, Vol 45, Issue 5, p1316
- ISSN
1053-1807
- Publication type
journal article
- DOI
10.1002/jmri.25506